Histological signatures map anti-fibrotic factors in mouse and human lungs.

Fibrosis is a process in which healthy, functional tissue gets replaced by tough, collagen-rich scar tissue. It can happen in almost any organ after injury, and in the lungs, it can seriously impair breathing. Idiopathic pulmonary fibrosis, a chronic and often fatal lung disease, is one of the most serious human examples of this process. Interestingly, lab mice given a lung-injuring drug called bleomycin don't just develop permanent scarring — their lungs actually go through a predictable sequence of injury followed by natural healing and scar resolution. Researchers reasoned that carefully studying this recovery process, stage by stage, might reveal which biological features actively drive scarring forward, and which ones help reverse it — insights that could be relevant to human fibrotic disease as well. To investigate, the team used detailed imaging to precisely track how the physical structure of lung scar tissue changed over time after injury, mapping it as a step-by-step trajectory from healthy, organized tissue to disordered scarred tissue, and back again during natural healing. This confirmed that the scarring process, at least at this stage, is reversible, following a structured path rather than random deterioration. Next, the researchers used advanced single-cell sequencing to identify which specific cells were active at each stage of this journey. They discovered two important types of fibroblasts, the cells primarily responsible for producing the collagen matrix involved in scarring. One type, marked by a gene called Csmd1, was especially active during the early, matrix-building phase of injury. A second type, marked by the gene Cd248, became more prominent later, during the healing and scar-resolving phase — suggesting these "pro-resolving" fibroblasts play an active role in cleaning up and reversing fibrosis. Using a spatial mapping technique that shows not just which genes are active but exactly where in the tissue they're active, the researchers found that these two fibroblast types created distinct local neighborhoods within the lung tissue, each with its own distinctive molecular environment — one associated with active fibrosis, and one associated with resolution. To test whether the "pro-resolving" fibroblasts were more than just bystanders, the researchers introduced them directly into injured mouse lungs and found that doing so measurably reduced fibrosis, suggesting these cells can be actively therapeutic rather than passive markers of the process. Digging further into the molecular signals involved, the team identified two specific proteins, SERPINE2 and PI16, associated with these fibroblast neighborhoods, and showed that manipulating them could influence fibrosis in human lung tissue samples studied outside the body. Finally, the researchers examined lung tissue from real patients with idiopathic pulmonary fibrosis and found similar fibroblast types and spatial neighborhoods to those identified in mice, suggesting these findings are directly relevant to human disease. Altogether, this research creates a detailed map of the cellular and molecular factors that push lung scarring forward versus those that help resolve it, and identifies specific fibroblast types and proteins that could become new therapeutic targets for treating fibrotic lung disease in humans.